BIOTAGE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 165.5 SEK | +0.49% |
|
+4.42% | +23.78% |
| Apr. 25 | Transcript : Biotage AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
| Apr. 25 | Biotage AB Approves a Dividend, Payable on May 3, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,085 | 9,063 | 17,288 | 12,240 | 10,697 | 13,241 | - | - |
| Enterprise Value (EV) 1 | 8,154 | 8,802 | 17,127 | 12,016 | 10,362 | 12,768 | 12,462 | 12,009 |
| P/E ratio | 43.2 x | 51.7 x | 83.7 x | 45.9 x | 40.2 x | 47.9 x | 37.2 x | 28.6 x |
| Yield | - | 1.08% | 0.59% | 0.86% | 1.2% | 1.12% | 1.27% | 1.45% |
| Capitalization / Revenue | 7.34 x | 8.3 x | 14 x | 7.82 x | 5.74 x | 6.09 x | 5.55 x | 4.94 x |
| EV / Revenue | 7.4 x | 8.06 x | 13.9 x | 7.67 x | 5.57 x | 5.87 x | 5.22 x | 4.48 x |
| EV / EBITDA | 28.9 x | 31.4 x | 47.8 x | 28 x | 20 x | 21.7 x | 19 x | 14.8 x |
| EV / FCF | 35 x | 42.1 x | 57.7 x | 39 x | 53.7 x | 42.2 x | 30 x | 19.3 x |
| FCF Yield | 2.86% | 2.37% | 1.73% | 2.56% | 1.86% | 2.37% | 3.34% | 5.18% |
| Price to Book | 9.23 x | 9.15 x | 12.5 x | 7.5 x | 2.71 x | 3.49 x | 3.22 x | 3.03 x |
| Nbr of stocks (in thousands) | 65,202 | 65,202 | 65,984 | 65,984 | 80,008 | 80,008 | - | - |
| Reference price 2 | 124.0 | 139.0 | 262.0 | 185.5 | 133.7 | 165.5 | 165.5 | 165.5 |
| Announcement Date | 2/7/20 | 2/12/21 | 2/11/22 | 2/15/23 | 2/15/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,101 | 1,092 | 1,232 | 1,566 | 1,862 | 2,174 | 2,387 | 2,678 |
| EBITDA 1 | 282.5 | 280.1 | 358 | 429 | 518 | 588 | 657 | 809 |
| EBIT 1 | 208.1 | 206.2 | 283 | 327 | 369 | 421.5 | 493.9 | 594.1 |
| Operating Margin | 18.89% | 18.88% | 22.97% | 20.88% | 19.82% | 19.38% | 20.69% | 22.18% |
| Earnings before Tax (EBT) 1 | 212 | 222.7 | 269 | 348 | 303 | 355 | 458.1 | 594.3 |
| Net income 1 | 186.8 | 175.3 | 205 | 268 | 246 | 277 | 357.4 | 464 |
| Net margin | 16.96% | 16.05% | 16.64% | 17.11% | 13.21% | 12.74% | 14.97% | 17.33% |
| EPS 2 | 2.870 | 2.690 | 3.130 | 4.040 | 3.330 | 3.452 | 4.449 | 5.784 |
| Free Cash Flow 1 | 233.1 | 208.9 | 297 | 308 | 193 | 302.5 | 415.7 | 621.5 |
| FCF margin | 21.17% | 19.13% | 24.11% | 19.67% | 10.37% | 13.91% | 17.41% | 23.21% |
| FCF Conversion (EBITDA) | 82.52% | 74.6% | 82.96% | 71.79% | 37.26% | 51.45% | 63.27% | 76.82% |
| FCF Conversion (Net income) | 124.79% | 119.17% | 144.88% | 114.93% | 78.46% | 109.22% | 116.29% | 133.94% |
| Dividend per Share 2 | - | 1.500 | 1.550 | 1.600 | 1.600 | 1.850 | 2.110 | 2.400 |
| Announcement Date | 2/7/20 | 2/12/21 | 2/11/22 | 2/15/23 | 2/15/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 341 | 386 | 395 | 401 | 384 | 361 | 409 | 449 | 643 | 480 | 498.5 | 505.6 | 690.4 |
| EBITDA 1 | 91 | 124 | - | 122 | - | 80 | 83 | 110 | 194 | 112 | 121.8 | 122.6 | 230.5 |
| EBIT 1 | 70 | 101 | 98 | 102 | 41 | 54 | 53 | 65 | 148 | 81 | 78 | 68 | 205 |
| Operating Margin | 20.53% | 26.17% | 24.81% | 25.44% | 10.68% | 14.96% | 12.96% | 14.48% | 23.02% | 16.88% | 15.65% | 13.45% | 29.69% |
| Earnings before Tax (EBT) 1 | 66 | 92 | 75 | 85 | 96 | 56 | 44 | 46 | - | 42 | 53 | 43 | 180 |
| Net income 1 | 46 | 71 | 57 | 65 | - | 43 | 34 | 38 | 131 | 33 | 53.75 | 53.75 | 139.5 |
| Net margin | 13.49% | 18.39% | 14.43% | 16.21% | - | 11.91% | 8.31% | 8.46% | 20.37% | 6.88% | 10.78% | 10.63% | 20.21% |
| EPS 2 | 0.6900 | 1.080 | 0.8700 | 0.9800 | 1.110 | 0.6500 | 0.4900 | 0.4800 | 1.640 | 0.4200 | 0.5300 | 0.4300 | 1.740 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/11/22 | 4/28/22 | 7/19/22 | 11/2/22 | 2/15/23 | 4/27/23 | 7/17/23 | 10/25/23 | 2/15/24 | 4/25/24 | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 69.2 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 261 | 161 | 224 | 335 | 473 | 780 | 1,232 |
| Leverage (Debt/EBITDA) | 0.245 x | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 233 | 209 | 297 | 308 | 193 | 303 | 416 | 622 |
| ROE (net income / shareholders' equity) | 23.7% | 18.8% | 17.4% | 17.8% | 9.29% | 7.83% | 9.39% | 11.6% |
| ROA (Net income/ Total Assets) | - | - | 12% | 12.4% | 6.77% | 5.97% | 7.59% | 8.49% |
| Assets 1 | - | - | 1,713 | 2,166 | 3,635 | 4,636 | 4,708 | 5,468 |
| Book Value Per Share 2 | 13.40 | 15.20 | 20.90 | 24.70 | 49.40 | 47.40 | 51.50 | 54.70 |
| Cash Flow per Share 2 | 4.270 | 4.140 | 5.070 | 5.740 | 3.840 | 4.500 | 5.430 | 9.600 |
| Capex 1 | 45.5 | 60.9 | 56 | 72 | 91 | 113 | 125 | 135 |
| Capex / Sales | 4.13% | 5.58% | 4.55% | 4.6% | 4.89% | 5.2% | 5.25% | 5.04% |
| Announcement Date | 2/7/20 | 2/12/21 | 2/11/22 | 2/15/23 | 2/15/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
165.5
SEK
Average target price
186.7
SEK
Spread / Average Target
+12.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.78% | 1.21B | |
| -12.91% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -18.10% | 682M | |
| -7.14% | 716M | |
| -.--% | 301M |
- Stock Market
- Equities
- BIOT Stock
- Financials Biotage AB
